Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzan Stelloo

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Endocrine-Related Cancer|March 14, 2019
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancersSuzan Stelloo, Andries M Bergman, Wilbert Zwart
Trends in Biotechnology|December 23, 2020
RNA-Centric Methods: Toward the Interactome of Specific RNA TranscriptsCathrin Gräwe, Suzan Stelloo, Femke A H van Hout, et al.
Genomics Data|March 17, 2016
Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancerEkaterina Nevedomskaya, Suzan Stelloo, Henk G van der Poel, et al.
Oncotarget|April 21, 2016
mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinomaSuzan Stelloo, Joyce Sanders, Ekaterina Nevedomskaya, et al.
Endocrine-Related Cancer|December 6, 2019
Androgen modulation of XBP1 is functionally driving part of the AR transcriptional programSuzan Stelloo, Simon Linder, Ekaterina Nevedomskaya, et al.
Cancer Research|August 23, 2014
Complex formation and function of estrogen receptor α in transcription requires RIP140Meritxell Rosell, Ekaterina Nevedomskaya, Suzan Stelloo, et al.
EMBO Molecular Medicine|September 29, 2015
Androgen receptor profiling predicts prostate cancer outcomeSuzan Stelloo, Ekaterina Nevedomskaya, Henk G van der Poel, et al.
Life Science Alliance|January 9, 2019
Optimized ChIP-seq method facilitates transcription factor profiling in human tumorsAbhishek A Singh, Karianne Schuurman, Ekaterina Nevedomskaya, et al.
Cell Reports. Medicine|January 19, 2024
Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potentialAnouk M D Becker, Annika H Decker, Georgina Flórez-Grau, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling outputStacey Ep Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Endocrine-Related Cancer|March 14, 2019
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancersSuzan Stelloo, Andries M Bergman, Wilbert Zwart
Trends in Biotechnology|December 23, 2020
RNA-Centric Methods: Toward the Interactome of Specific RNA TranscriptsCathrin Gräwe, Suzan Stelloo, Femke A H van Hout, et al.
Genomics Data|March 17, 2016
Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancerEkaterina Nevedomskaya, Suzan Stelloo, Henk G van der Poel, et al.
Oncotarget|April 21, 2016
mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinomaSuzan Stelloo, Joyce Sanders, Ekaterina Nevedomskaya, et al.
Endocrine-Related Cancer|December 6, 2019
Androgen modulation of XBP1 is functionally driving part of the AR transcriptional programSuzan Stelloo, Simon Linder, Ekaterina Nevedomskaya, et al.
Cancer Research|August 23, 2014
Complex formation and function of estrogen receptor α in transcription requires RIP140Meritxell Rosell, Ekaterina Nevedomskaya, Suzan Stelloo, et al.
EMBO Molecular Medicine|September 29, 2015
Androgen receptor profiling predicts prostate cancer outcomeSuzan Stelloo, Ekaterina Nevedomskaya, Henk G van der Poel, et al.
Life Science Alliance|January 9, 2019
Optimized ChIP-seq method facilitates transcription factor profiling in human tumorsAbhishek A Singh, Karianne Schuurman, Ekaterina Nevedomskaya, et al.
Cell Reports. Medicine|January 19, 2024
Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potentialAnouk M D Becker, Annika H Decker, Georgina Flórez-Grau, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling outputStacey Ep Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Pageof 3